5-Amino-1MQ
Sexual & Body CompositionAlso known as: 5-Amino-1-Methylquinolinium, 5A1MQ, NNMT Inhibitor
Mechanism
5-Amino-1MQ is a small molecule that blocks an enzyme called NNMT (nicotinamide N-methyltransferase) which is overactive in fat tissue and contributes to obesity and metabolic dysfunction. By inhibiting NNMT, it boosts cellular NAD+ levels, shifts the body toward burning fat instead of storing it, and increases energy expenditure. In animal studies, it has produced significant fat loss without affecting food intake or causing observable side effects.
Technical detail
5-Amino-1-methylquinolinium is a selective, cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide using SAM as a methyl donor, producing 1-methylnicotinamide (MNA) and SAH. NNMT is overexpressed in white adipose tissue in obesity. Inhibition reduces intracellular MNA, increases NAD+ availability (supporting SIRT1-mediated metabolic regulation), and suppresses de novo lipogenesis in adipocytes. In DIO mouse models, treatment significantly reduced body weight, white adipose mass, and adipocyte size while increasing energy expenditure and improving insulin sensitivity and glucose tolerance — without affecting food intake. High selectivity: does not inhibit related SAM-dependent methyltransferases or enzymes in the NAD+ salvage pathway.
Effects
METABOLIC: Primary target system. Inhibits NNMT (nicotinamide N-methyltransferase), an enzyme overexpressed in white adipose tissue in obesity. NNMT drains cellular NAD+ by methylating nicotinamide to 1-methylnicotinamide (MNA) — inhibiting it increases intracellular NAD+ levels, restoring SIRT1-mediated metabolic regulation. In DIO (diet-induced obese) mouse models: significantly reduced body weight, white adipose mass, and adipocyte size without affecting food intake (Neelakantan et al., 2018, PMID: 29180435). Increased whole-body energy expenditure — mice burned more calories without eating less. Improved insulin sensitivity and glucose tolerance. Normalized fasting blood glucose to lean-animal levels when combined with dietary intervention. Suppresses de novo lipogenesis (fat creation) in adipocytes while promoting fat oxidation. MUSCULOSKELETAL: NNMT is also expressed in skeletal muscle. Inhibition may improve muscle NAD+ pools, supporting mitochondrial function and exercise capacity (theoretical, based on NAD+ biology). NNMT inhibition in muscle promotes differentiation of satellite cells and muscle regeneration in animal models. ENDOCRINE: Improved insulin sensitivity is the primary endocrine effect — insulin resistance is a hallmark of obesity and metabolic syndrome. By restoring NAD+ levels, may indirectly support testosterone production (NAD+ is required for steroidogenesis). CARDIOVASCULAR: Weight loss and improved metabolic health reduce cardiovascular risk. Improved lipid profiles observed in treated animals. NEUROLOGICAL: NAD+ is critical for neuronal function — increasing brain NAD+ pools may support cognitive health, though 5-Amino-1MQ's ability to cross the BBB is unknown. IMMUNE: Reduced adipose-derived inflammation — obesity drives chronic low-grade inflammation via adipokine dysregulation. NNMT inhibition reduces inflammatory markers associated with metabolic syndrome. HEPATIC: Reduced hepatic steatosis (fatty liver) in treated animals — likely secondary to improved overall fat metabolism and reduced lipogenesis. Tier 3: Practitioner reports describe noticeable fat loss (particularly visceral fat) within 4-8 weeks at standard dosing. Often combined with dietary modification for synergistic effects. Most practitioners use oral capsules rather than injection.
Practitioner Guide
DOSING TIPS: Most commonly administered orally as capsules. Typical dose: 50-100mg once daily. Some practitioners use 50mg twice daily. Start at 50mg/day and increase based on tolerance and response. Take in the morning — potential mild stimulatory effect from increased metabolic rate. Can be taken with or without food, though some practitioners recommend with food to reduce any GI sensitivity. RECONSTITUTION: N/A — typically supplied as oral capsules from compounding pharmacies. For research: available as lyophilized powder. Not typically used as an injectable in clinical practice. SUPPLEMENT SYNERGIES: Pairs exceptionally well with GLP-1 agonists (semaglutide, tirzepatide) for multi-pathway fat loss — GLP-1s reduce appetite centrally while 5-Amino-1MQ increases energy expenditure peripherally. Combine with NAD+ precursors (NMN/NR) for comprehensive NAD+ optimization (5-Amino-1MQ prevents NAD+ drain, NMN/NR provide NAD+ substrate). Stack with L-carnitine for enhanced fatty acid transport into mitochondria. Berberine or metformin complement via AMPK pathway (different mechanism). CYCLING: Recommended — 8-12 weeks on, 4 weeks off. Limited data on long-term continuous use. NNMT may adapt to chronic inhibition (theoretical). Most practitioners report best results in the first 8 weeks. STACKING: Fat loss stack: 5-Amino-1MQ + MOTS-c + AOD-9604. Metabolic optimization: 5-Amino-1MQ + NMN + Berberine. Comprehensive: 5-Amino-1MQ + semaglutide/tirzepatide + L-carnitine. Body recomposition: 5-Amino-1MQ + Ipamorelin/CJC-1295. CONTRAINDICATION NUANCES: Not a peptide — it is a small molecule quinolinium salt. No human clinical trials — all dosing is extrapolated from animal data and practitioner experience. Patients with liver disease should use with caution (NNMT is hepatically expressed; effects of inhibition in compromised liver unknown). May affect nicotinamide/niacin metabolism — monitor B3 status. Potential interactions with drugs metabolized via methylation pathways (theoretical). STORAGE: Capsules at room temperature, away from moisture and light. Powder: refrigerate for long-term stability. PATIENT EDUCATION: This is not a peptide — it is a small molecule that happens to be sold by peptide suppliers. It works differently from every other fat loss compound: instead of suppressing appetite (GLP-1s) or mobilizing stored fat (GH peptides), it prevents your cells from wasting NAD+ and shifts your metabolism toward burning fat. No human trials exist — this is cutting-edge but unproven in humans. Expect gradual results over 4-8 weeks, not overnight fat loss. Works best combined with exercise and moderate caloric deficit.
Research Summary
TIER 1 (Gold Standard): Neelakantan et al., 2018 — Selective and membrane-permeable small molecule inhibitors of NNMT reverse high fat diet-induced obesity in mice (PMID: 29180435, Biochemical Pharmacology). This is the foundational paper demonstrating 5-Amino-1MQ's anti-obesity effects. TIER 2 (Strong): Kraus et al., 2014 — NNMT overexpression in adipose tissue and obesity (PMID: 24718898). Pissios, 2017 — NNMT roles in metabolism (PMID: 28208520). Hong et al., 2015 — NNMT in energy homeostasis. Kannt et al., 2015 — NNMT as anti-obesity target. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (Scientific Reports, 2021). TIER 3 (Moderate): Practitioner protocols from metabolic optimization and weight loss clinics. Case series showing fat loss in combination with lifestyle modification. International compounding pharmacy protocols. Community reports consistent with animal data — fat loss without appetite suppression. KEY FINDINGS: (1) NNMT is a validated obesity target with strong preclinical evidence. (2) 5-Amino-1MQ is the lead compound with demonstrated in-vivo efficacy. (3) Mechanism is unique — NAD+ restoration rather than appetite suppression or lipolysis stimulation. (4) No human clinical trials exist — a critical gap. (5) Safety profile appears clean in animals (no food intake changes, no observed adverse effects). GAPS: No human pharmacokinetic, efficacy, or safety data. Optimal oral dosing unknown. Long-term effects of chronic NNMT inhibition. Tissue-specific effects (muscle vs. adipose vs. liver). Drug interactions. ACTIVE TRIALS: No registered trials on ClinicalTrials.gov for 5-Amino-1MQ specifically.